Granisetron Stada (Granisetron)

Granisetron Stada is indicated for the prevention of nausea and vomiting in specific clinical situations, particularly those related to cancer therapy and surgery.

• Prevention of chemotherapy‑induced nausea and vomiting (CINV) in adult patients.
• Prevention of postoperative nausea and vomiting (PONV) after general anesthesia.
• Use as part of a multimodal antiemetic regimen when high emetogenic risk is anticipated.
• Management of nausea and vomiting associated with radiotherapy in certain protocols.
• Adjunct therapy for nausea related to opioid analgesics when other measures are insufficient.
• Prophylactic use in patients receiving highly emetogenic chemotherapy agents such as cisplatin.

The safety profile of Granisetron Stada includes both frequently observed and less common adverse reactions that may require medical attention.

Common

• Headache, which may be mild to moderate and transient.
• Constipation, characterized by infrequent bowel movements or hard stools.
• Diarrhea, presenting as occasional loose or watery stools.
• Fatigue, a feeling of reduced energy or tiredness.
• Dizziness, a sensation of light‑headedness or imbalance.
• Dry mouth, reduced salivation causing a parched feeling.

Serious

• Severe allergic reactions, such as anaphylaxis, widespread rash, or facial swelling, requiring immediate medical care.
• Cardiac effects, including arrhythmias or QT interval prolongation, particularly in patients with existing heart disease or electrolyte disturbances.

When prescribing Granisetron Stada, clinicians should consider several precautionary measures to ensure safe and effective use.

• Assess patient history for hypersensitivity to granisetron or other 5‑HT3 antagonists.
• Use caution in patients with known cardiac conduction disorders or prolonged QT interval.
• Monitor electrolyte balance, especially potassium, magnesium, and calcium levels.
• Evaluate renal and hepatic function, adjusting dose if significant impairment is present.
• Discuss potential pregnancy and lactation considerations, as safety data are limited.
• Advise patients to report any signs of severe allergic reaction or cardiac symptoms promptly.

Granisetron Stada may interact with other medicines; understanding these interactions helps minimize adverse effects and therapeutic failures.

Avoid

• Concomitant use with other QT‑prolonging agents (e.g., certain antiarrhythmics, antipsychotics, macrolide antibiotics).
• Strong CYP3A4 inhibitors that could increase granisetron plasma concentrations.

Use with caution

• CYP3A4 inducers such as rifampin, which may reduce granisetron effectiveness.
• Other serotonergic drugs, although the risk of serotonin syndrome is low, monitoring is advised.
• Medications that affect cardiac conduction, requiring ECG monitoring when combined.